Apogee Therapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
APGE Nasdaq 2830 www.apogeetherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Apogee Therapeutics, Inc.

Apogee Therapeutics' Investigational Atopic Dermatitis Potential Shows Strong Tolerability, Extended Half-Life in Early Trial - Mar 3rd, 2025 5:16 pm
Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2024 Financial Results - Mar 3rd, 2025 11:05 am
Apogee Therapeutics Announces Positive Interim Phase 1 Results from the APG990 Healthy Volunteer Trial, Unlocking Potential Maintenance Dosing Every Three and Six Months for APG279 (APG777 + APG990) - Mar 3rd, 2025 11:00 am
Is Apogee Therapeutics, Inc. (APGE) the Best Small-Cap Stock to Buy Now? - Mar 1st, 2025 2:22 pm
Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1 Healthy Volunteer Trial for APG990 and Provide Combination Strategy Update on March 3, 2025 - Feb 28th, 2025 9:00 pm
Apogee Therapeutics to Participate in Upcoming March Investor Conferences - Feb 25th, 2025 12:30 pm
Apogee Therapeutics Announces First Patient Dosed in Part B of Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis - Feb 3rd, 2025 12:00 pm
Here’s Why Apogee Therapeutics, Inc. (APGE) Will Double in 2025 - Jan 30th, 2025 8:44 pm
Apogee Therapeutics to Participate at the Guggenheim SMID Cap Biotech Conference - Jan 29th, 2025 12:30 pm
This Apogee Therapeutics Insider Increased Their Holding In The Last Year - Dec 25th, 2024 11:33 am
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG333, its Novel Half-Life Extended TSLP Antibody for the Treatment of Respiratory and Broader I&I Conditions - Dec 10th, 2024 12:00 pm
Apogee Therapeutics Advances in I&I Disease Treatments - Dec 3rd, 2024 11:52 am
Apogee Therapeutics Highlights Progress and Best-in-Class Potential of Novel Biologic Programs for I&I Diseases at 2024 Inaugural R&D Day - Dec 2nd, 2024 11:00 am
Apogee Therapeutics Announces Agenda for Virtual R&D Day - Nov 29th, 2024 6:00 pm
Apogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024 - Nov 18th, 2024 12:30 pm
Apogee Therapeutics (NASDAQ:APGE) Is In A Good Position To Deliver On Growth Plans - Nov 14th, 2024 12:22 pm
Apogee reports Q3 EPS, expects cash to fund operations into Q1 of 2028 - Nov 13th, 2024 12:21 pm
Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2024 Financial Results - Nov 12th, 2024 12:00 pm
Apogee Therapeutics to Participate in Upcoming November Investor Conferences - Nov 4th, 2024 12:30 pm
Apogee Therapeutics Announces Results Up to 9 Months from Phase 1 Trial of APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases - Oct 24th, 2024 12:00 pm